

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE THREE MONTHS ENDED 31 MARCH 2022 IN RELATION TO ISSUANCES OF CORPORATE BONDS AND MEDIUM TERM NOTES IN THE PRC

Reference is made to: (i) the announcements of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 7 December 2018 and 23 May 2019 in relation to, among others, the proposed public issuance of corporate bonds by China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly owned subsidiary of the Company in the PRC and the completion of the public issuance of the first tranche of 2019 corporate bonds in the PRC; (ii) the announcements dated 13 November 2019 and 30 October 2020 in relation to, among others, the completion of the public issuance of 2019 first tranche perpetual corporate bonds in the PRC and the proposed public issuance of 2020 first tranche perpetual corporate bonds in the PRC by CR Pharmaceutical Holdings; (iii) the announcement dated 23 June 2021 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2021 by CR Pharmaceutical Holdings; and (iv) the announcement dated 21 January 2022 in relation to, among others, the completion of the public issuance of the 2022 first tranche corporate bonds in the PRC by CR Pharmaceutical Holdings (the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuances of corporate bonds and medium term notes in the PRC, CR Pharmaceutical Holdings has published its audited report for the year ended 31 December 2021 and unaudited financial statements for the three months ended 31 March 2022 on the website of Beijing Financial Assets Exchange and has published its audited report for the year ended 31 December 2021 on the website of the Shanghai Stock Exchange.

The unaudited financial statements of CR Pharmaceutical Holdings for the three months ended 31 March 2022 (the “**Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings**”) are enclosed to this announcement for the Company’s shareholders’ information only. The Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 29 April 2022

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mdm. Weng Jingwen and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mr. Tan Ying, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS
COMPANY LIMITED (華潤醫藥控股有限公司)**
BALANCE SHEET IN ACCORDANCE WITH THE PRC STANDARDS
MARCH 2022

Adjusted to denominated currency

Unit of monetary amounts: RMB1

Item	Closing Balance	Opening Balance	Item	Closing Balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	1,439,547,807.17	1,993,226,097.49	Short-term borrowings	-	-
Held-for-trading financial assets	241,130,277.78	235,130,277.78	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	-	-
Notes receivable	-	-	Including: Notes payable	-	-
Accounts receivable	-	-	Accounts payable	-	-
Financing receivables	-	-	Receipts in advance	-	-
Prepayment	(73,943.64)	-	Contract liabilities	-	-
Other receivables	30,582,607,098.59	30,140,050,020.82	Staff remuneration payable	41,001,125.76	57,401,351.99
Including: Interest receivable	-	-	Including: Wages payable	-	51,831,798.00
Dividends receivable	3,616,748,449.32	3,616,748,449.32	Benefits payable	-	-
Inventory	-	-	Taxation payable	4,002,935.15	8,945,618.86
Including: Raw materials	-	-	Including: Tax payable	4,002,935.15	8,945,618.86
Goods in stock (finished products)	-	-	Other payables	16,263,388,661.82	18,371,434,374.63
Contract assets	-	-	Including: Interest payable	28,252,777.78	-
Assets held for sale	-	-	Dividends payable	1,924,147,500.00	1,924,147,500.00
Non-current assets due within one year	-	-	Insurance contract liabilities	-	-
Other current assets	-	-	Liabilities held for sale	-	-
			Non-current liabilities due within one year	2,504,632,227.58	1,311,697,361.70
			Other current liabilities	-	-
Total current assets	32,263,211,239.90	32,368,406,396.09	Total current liabilities	18,813,024,950.31	19,749,478,707.18
Non-current assets:			Non-current liabilities:		
Other debt investments	-	-	Long-term borrowings	1,801,890,000.00	1,620,000,000.00
Debt investments	-	-	Bonds payable	4,689,347,320.45	2,500,000,000.00
Long-term receivables	-	-	Long-term payables	-	1,585,000,000.00
Other equity instruments investments	-	-	Including: Long-term payables	-	1,585,000,000.00
Long-term equity investments	12,236,413,223.56	12,195,772,430.21	Special payables	-	-
Investment properties	-	-	Long-term employee remuneration payable	368,560,000.00	356,930,000.00
Other non-current financial assets	-	-	△Deferred revenue	-	-
Fixed assets	2,732,367.22	2,828,677.68	Estimated liabilities	-	-
Including: Disposal of fixed assets	-	-	Deferred income tax liabilities	1,282,569.45	1,282,569.45
Right-of-use assets	27,659,170.97	27,659,170.97	Lease liabilities	28,996,107.59	19,798,293.92
Construction in progress	-	-	Other non-current liabilities	-	-
Including: Construction materials	-	-	Including: Special reserve	-	-
Biological assets for production	-	-	Total non-current liabilities	6,890,075,997.49	6,083,010,863.37
Oil and gas assets	-	-	Total liabilities	25,703,100,947.80	25,832,489,570.55
Intangible assets	253,207.58	313,655.69	Owners' equity (or shareholders' equity):		
Including: Land use right	-	-	Paid-in capital (equity)	15,000,000,000.00	15,000,000,000.00
Development expenses	-	-	State-owned capital	-	-
Goodwill	-	-	Collective capital	-	-
Long-term deferred expenses	-	-	Legal person capital	15,000,000,000.00	15,000,000,000.00
Deferred income tax assets	334,234.16	334,234.16	Including: State-owned legal person capital	15,000,000,000.00	15,000,000,000.00
Other non-current assets	27,659,923.44	27,641,773.44	Collectively-owned legal person capital	-	-
Including: Contract assets	-	-	Individual's capital	-	-
			Foreign capital	-	-
			Other equity instruments	2,997,774,396.22	2,997,774,396.22
			Capital surplus	36,455,821.78	36,455,821.78
			Less: treasury shares	-	-
			Other comprehensive income	9,690,416.58	9,690,416.58
			Including: Differences on translation of foreign currency statements	-	-
			Surplus reserves	633,183,434.60	633,183,434.60
Total non-current assets	12,295,052,126.93	12,254,549,942.15	Special reserves	-	-
			Undistributed profits	178,058,349.85	113,362,698.51
			Total equity attributable to owners of the parent company	18,855,162,419.03	18,790,466,767.69
			△Minority interests	-	-
			Total owners' equity	18,855,162,419.03	18,790,466,767.69
Total assets	44,558,263,366.83	44,622,956,338.24	Total liabilities and owners' equity	44,558,263,366.83	44,622,956,338.24

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS
COMPANY LIMITED (華潤醫藥控股有限公司)**
STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH THE PRC STANDARDS
MARCH 2022

Adjusted to denominated currency

Unit of monetary amounts: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Operating revenue	-	-
Including: Revenue from principal businesses	-	-
Revenue from other businesses	-	-
II. Operating costs	-	-
Including: Costs for principal businesses	-	-
Costs for other businesses	-	-
Tax and surcharge	106,235.63	179,089.81
Selling expenses	-	-
Management expenses	22,058,979.63	30,616,289.26
Including: Entertainment expenses	23,544.70	54,024.90
Research and development expenses	1,061,823.92	15,462,503.72
Finance costs	(57,862,451.61)	(24,878,280.07)
Including: Interest expenses	41,312,039.88	52,947,496.61
Interest income	65,765,497.45	105,831,985.74
Net Loss from exchange (net gain is represented by “-”)	(35,952,030.12)	27,993,135.60
Other revenue	232,321.35	240,506.94
Gain from investment (loss is represented by “-”)	41,728,494.93	21,614,529.21
Including: Gains from investment in associates and joint ventures	40,640,793.35	21,156,202.84
Gain from derecognition of financial assets at amortised costs	-	-
Net gains from hedging exposure (loss is represented by “-”)	-	-
Add: gains from changes in fair values (loss is represented by “-”)	-	-
Impairment losses of assets	-	-
Loss on credit impairment	-	-
Gains from disposal of assets	-	-
III. Operating profits (loss is represented by “-”)	76,596,228.71	475,433.43
Add: Non-operating income	-	-
Including: Gains from exchanging non-monetary assets	-	-
Government subsidies	-	-
Less: Non-operating expenses	-	-
Including: Loss on exchanging non-monetary assets	-	-
IV. Total profits (total loss is represented by “-”)	76,596,228.71	475,433.43
Less: Income tax expenses	11,900,577.37	-
V. Net profits (net loss is represented by “-”)	64,695,651.34	475,433.43
Including: Net gains of the absorbed party before business combination under common control	-	-
Net profits attributable to the owners of the parent company	64,695,651.34	475,433.43
* Gains and losses of minority interests	-	-
Profit attributable to holders of perpetual capital instruments	-	-

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS
COMPANY LIMITED (華潤醫藥控股有限公司)**
STATEMENT OF CASH FLOWS IN ACCORDANCE WITH THE PRC STANDARDS
MARCH 2022

Adjusted to denominated currency

Unit of monetary amounts: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	-	-
Refund of taxes and levies	232,321.35	254,937.36
Cash received relating to other operating activities	1,112,928.71	200,000,000.00
Sub-total of cash inflows from operating activities	1,345,250.06	200,254,937.36
Cash paid for goods purchased and services received	76,938.24	100,575.94
Cash paid to and for employees	33,148,998.07	21,526,015.23
Payments of all types of taxes	20,379,191.51	28,474,314.54
Cash payments relating to other operating activities	15,272,366.85	279,690,012.12
Sub-total of cash outflows from operating activities	68,877,494.67	329,790,917.83
Net cash flow from operating activities	(67,532,244.61)	(129,535,980.47)
II. CASH FLOW FROM INVESTING ACTIVITIES:		
Cash received from investment recovery	3,800,000,000.00	8,848,000,000.00
Cash received from returns on investments	71,978,037.65	32,723,009.84
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	-	-
Net cash received from disposals of subsidiaries and other operating units	-	-
Cash received relating to other investing activities	-	1,927,596.10
Sub-total of cash inflows from investing activities	3,871,978,037.65	8,882,650,605.94
Cash paid to acquire fixed assets, intangible assets and other long-term assets	-	26,226.08
Cash paid for investments	4,245,832,600.00	8,550,000,000.00
Net cash paid for acquisition of subsidiaries and other operational units	-	-
Cash payments relating to other investing activities	-	-
Sub-total of cash outflows from investing activities	4,245,832,600.00	8,550,026,226.08
Net cash flow from investing activities	(373,854,562.35)	332,624,379.86
III. Cash flow from financing activities:		
Cash received from capital contribution	-	-
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	-	-
Cash received from issuance of bonds	2,000,000,000.00	-
Cash payments relating to other financing activities	686,001,646.83	894,021,664.91
Sub-total of cash inflows from financing activities	2,686,001,646.83	894,021,664.91
Cash payments for debts settlement	2,000,000,000.00	500,000,000.00
Cash payments for distribution of dividends, profits, or interest expenses	13,345,147.49	3,085,131.94
Including: Dividends and profits paid by subsidiaries to minority shareholders	-	-
Cash payments relating to other financing activities	784,917,600.00	815,866,476.24
Sub-total of cash outflows from financing activities	2,798,262,747.49	1,318,951,608.18
Net cash flow from financing activities	(112,261,100.66)	(424,929,943.27)
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(10.68)	3.37
V. Net increase in cash and cash equivalents	(553,647,918.30)	(221,841,540.51)
Add: Opening balance of cash and cash equivalent	1,993,194,927.07	463,173,476.97
VI. Closing balance of cash and cash equivalents	1,439,547,008.77	241,331,936.46

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS
COMPANY LIMITED (華潤醫藥控股有限公司)**
**(CONSOLIDATED) BALANCE SHEET IN ACCORDANCE WITH
THE PRC STANDARDS
MARCH 2022**

Adjusted to denominated currency

Unit of monetary amounts: RMB1

Item	Closing Balance	Opening Balance	Item	Closing Balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	19,437,672,780.03	20,526,179,189.83	Short-term borrowings	36,525,799,601.87	30,507,311,413.77
Held-for-trading financial assets	10,136,351,462.64	9,801,332,802.09	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	45,813,981,318.39	43,151,256,527.59
Notes receivable	1,892,918,629.53	928,658,485.11	Including: Notes payable	11,830,466,894.29	11,962,852,593.04
Accounts receivable	60,152,394,075.94	54,199,668,263.46	Accounts payable	33,983,514,424.10	31,188,403,934.55
Financing receivables	23,775,752,572.23	23,108,452,972.30	Receipts in advance	514,657.01	-
Prepayment	5,437,786,671.60	3,539,432,294.49	Contract liabilities	3,830,209,280.30	2,908,167,885.90
Other receivables	6,146,371,925.73	5,446,685,467.69	Staff remuneration payable	1,763,658,963.76	2,354,327,062.76
Including: Interest receivable	234,722.71	286,441.27	Including: Wages payable	533,742,801.93	2,067,590,169.80
Dividends receivable	-	-	Benefits payable	-	18,145,025.85
Inventory	25,210,342,860.83	24,165,481,658.80	Taxation payable	1,120,135,746.57	1,403,817,561.93
Including: Raw materials	2,145,589,887.24	1,865,326,714.98	Including: Tax payable	1,090,551,682.12	1,349,926,552.65
Goods in stock (finished products)	20,726,032,283.24	20,433,269,981.00	Other payables	33,070,703,344.72	36,548,927,707.87
Contract assets	31,193,562.35	24,551,017.31	Including: Interest payable	148,835,364.47	95,211,531.97
Assets held for sale	-	-	Dividends payable	5,160,765,314.04	5,186,266,138.17
Non-current assets due within one year	741,268,656.66	889,233,946.74	Insurance contract liabilities	-	-
Other current assets	521,660,880.56	954,726,098.23	Liabilities held for sale	-	-
			Non-current liabilities due within one year	3,266,053,437.20	2,140,449,276.44
			Other current liabilities	212,946,886.02	388,289,208.32
Total current assets	153,483,714,078.10	143,584,402,196.05	Total current liabilities	125,604,003,235.84	119,402,546,644.58
Non-current assets:			Non-current liabilities:		
Other debt investments	-	-	Long-term borrowings	4,725,573,170.70	3,369,969,647.40
Debt investments	-	-	Bonds payable	4,689,347,320.45	2,500,000,000.00
Long-term receivables	918,817,057.65	934,101,433.99	Long-term payables	149,449,705.60	1,745,663,088.38
Other equity instruments investments	2,066,000.00	-	Including: Long-term payables	5,537,700.30	1,590,949,495.35
Long-term equity investments	4,839,686,067.77	4,783,911,962.80	Special payables	143,912,005.30	154,713,593.03
Investment properties	280,243,539.32	301,759,170.61	Long-term employee remuneration payable	870,520,081.31	889,904,354.49
Other non-current financial assets	780,897,023.39	791,262,045.57	△Deferred revenue	720,426,847.27	730,798,019.33
Fixed assets	14,208,880,487.05	14,411,812,372.84	Estimated liabilities	23,335,634.67	21,233,499.29
Including: Disposal of fixed assets	4,365,356.36	3,540,768.21	Deferred income tax liabilities	1,501,584,968.95	1,495,542,016.87
Right-of-use assets	1,162,382,799.46	1,158,730,879.53	Lease liabilities	738,034,173.58	737,343,645.18
Construction in progress	1,262,549,542.70	1,068,572,046.14	Other non-current liabilities	27,089,921.74	-
Biological assets for production	14,012,362.07	16,944,090.04	Including: Special reserve		
Oil and gas assets	-	-	Total non-current liabilities	13,445,361,824.27	11,490,454,270.94
Intangible assets	9,384,314,170.20	9,470,346,174.97	Total liabilities	139,049,365,060.12	130,893,000,915.52
Including: Land use right	3,144,844,909.55	3,163,316,473.06	Owners' equity (or shareholders' equity):		
Development expenses	1,241,837,871.55	1,172,096,372.84	Paid-in capital (equity)	15,000,000,000.00	15,000,000,000.00
Goodwill	20,359,539,845.31	20,359,539,845.29	State-owned capital		
Long-term deferred expenses	342,198,596.25	353,675,072.04	Collective capital		
Deferred income tax assets	1,039,802,629.88	1,041,908,930.22	Legal person capital	15,000,000,000.00	15,000,000,000.00
Other non-current assets	650,493,460.40	672,426,648.05	Including: State-owned legal person capital	15,000,000,000.00	15,000,000,000.00
Including: Contract assets	92,418,369.69	121,882,169.39	Collectively-owned legal person capital		
			Individual's capital		
			Foreign capital		
			Other equity instruments	2,997,774,396.22	2,997,774,396.22
			Capital surplus	433,004,647.24	433,004,647.23
			Less: treasury shares	85,947,804.19	-
			Other comprehensive income	(4,690,880.66)	(4,650,092.28)
			Including: Differences on translation of foreign currency statements	1,623,385.36	1,130,074.58
			Surplus reserves	408,097,998.59	408,097,998.59
Total non-current assets	56,487,721,452.78	56,537,087,044.93	Special reserves	1,144,412.75	1,113,502.83
			Undistributed profits	12,412,607,458.56	11,486,890,606.66
			Total equity attributable to owners of the parent company	31,161,990,228.51	30,322,231,059.25
			△Minority interests	39,760,080,242.26	38,906,257,266.21
			Total owners' equity	70,922,070,470.77	69,228,488,325.46
Total assets	209,971,435,530.88	200,121,489,240.98	Total liabilities and owners' equity	209,971,435,530.88	200,121,489,240.98

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS
COMPANY LIMITED (華潤醫藥控股有限公司)**
**(CONSOLIDATED) STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH
THE PRC STANDARDS**
MARCH 2022

Adjusted to denominated currency

Unit of monetary amounts: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Operating revenue	51,023,315,329.18	47,105,616,838.06
Including: Revenue from principal businesses	50,606,470,432.56	46,719,843,036.25
Revenue from other businesses	416,844,896.62	385,773,801.81
II. Operating costs	42,769,459,554.85	39,589,830,044.77
Including: Costs for principal businesses	42,541,774,027.34	39,440,575,699.56
Costs for other businesses	227,685,527.51	149,254,345.21
Tax and surcharge	216,392,673.83	199,727,800.13
Selling expenses	3,664,285,625.61	3,603,798,664.82
Management expenses	1,108,412,847.95	1,037,075,230.88
Including: Entertainment expenses	15,371,014.67	16,046,372.22
Research and development expenses	295,950,622.16	241,368,302.34
Finance costs	340,281,804.89	521,140,377.04
Including: Interest expenses	450,682,102.02	516,298,289.50
Interest income	99,221,777.17	53,619,959.05
Net Loss from exchange (net gain is represented by “-”)	(34,496,518.15)	27,848,043.11
Other revenue	85,964,367.09	62,722,851.81
Gain from investment (loss is represented by “-”)	54,076,004.89	67,209,451.62
Including: Gains from investment in associates and joint ventures	74,730,104.97	39,130,170.76
Gain from derecognition of financial assets at amortised costs	-	-
Net gains from hedging exposure (loss is represented by “-”)	-	-
Add: gains from changes in fair values (loss is represented by “-”)	22,722,235.24	30,613,264.60
Impairment losses of assets	22,583,469.24	36,603,060.16
Loss on credit impairment	288,608,368.79	168,706,656.85
Gains from disposal of assets	1,735,216.93	9,065,716.34
III. Operating profits (loss is represented by “-”)	2,481,838,186.02	1,876,977,985.45
Add: Non-operating income	8,656,319.89	20,582,631.42
Including: Gains from exchanging non-monetary assets	-	-
Government subsidies	44,216.00	815,679.07
Less: Non-operating expenses	11,763,604.74	6,925,291.11
Including: Loss on exchanging non-monetary assets	-	-
IV. Total profits (total loss is represented by “-”)	2,478,730,901.17	1,890,635,325.76
Less: Income tax expenses	532,154,555.46	372,073,136.58
V. Net profits (net loss is represented by “-”)	1,946,576,345.72	1,518,562,189.18
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	925,716,852.92	687,308,025.52
* Gains and losses of minority interests	1,020,859,492.80	831,254,163.66
Profit attributable to holders of perpetual capital instruments	-	-

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS
COMPANY LIMITED (華潤醫藥控股有限公司)**
**(CONSOLIDATED) STATEMENT OF CASH FLOWS IN ACCORDANCE WITH
THE PRC STANDARDS
MARCH 2022**

Adjusted to denominated currency

Unit of monetary amounts: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	49,071,392,538.87	48,177,047,119.47
Refund of taxes and levies	32,470,002.61	117,227,075.33
Cash received relating to other operating activities	3,565,624,481.42	4,881,644,085.58
Sub-total of cash inflows from operating activities	52,669,487,022.90	53,175,918,280.38
Cash paid for goods purchased and services received	46,095,276,272.51	44,232,077,420.79
Cash paid to and for employees	3,095,840,474.62	2,674,303,527.30
Payments of all types of taxes	2,047,174,004.52	1,970,815,516.66
Cash payments relating to other operating activities	6,261,281,531.37	8,863,144,622.64
Sub-total of cash outflows from operating activities	57,499,572,283.02	57,740,341,087.39
Net cash flow from operating activities	(4,830,085,260.12)	(4,564,422,807.01)
II. CASH FLOW FROM INVESTING ACTIVITIES:		
Cash received from investment recovery	3,914,775,626.48	6,152,530,540.42
Cash received from returns on investments	93,220,969.82	65,329,847.23
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	1,066,342.07	13,984,214.73
Net cash received from disposals of subsidiaries and other operating units	-	-
Cash received relating to other investing activities	4,757,500.04	49,577,716.99
Sub-total of cash inflows from investing activities	4,013,820,438.41	6,281,422,319.37
Cash paid to acquire fixed assets, intangible assets and other long-term assets	504,193,501.87	402,038,387.82
Cash paid for investments	4,205,100,000.00	6,790,422,136.71
Net cash paid for acquisition of subsidiaries and other operational units	5,265,705.33	255,438,911.39
Cash payments relating to other investing activities	-	2,116,422.41
Sub-total of cash outflows from investing activities	4,714,559,207.20	7,450,015,858.33
Net cash flow from investing activities	(700,738,768.79)	(1,168,593,538.96)
III. Cash flow from financing activities:		
Cash received from capital contribution	33,265,000.00	13,475,000.00
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	31,572,151,368.12	22,357,155,458.11
Cash received from issuance of bonds	2,000,000,000.00	-
Cash payments relating to other financing activities	4,090,987,851.26	4,796,127,940.72
Sub-total of cash inflows from financing activities	37,696,404,219.38	27,166,758,398.83
Cash payments for debts settlement	28,811,823,392.03	15,090,286,022.80
Cash payments for distribution of dividends, profits, or interest expenses	495,923,224.71	390,021,544.23
Including: Dividends and profits paid by subsidiaries to minority shareholders	-	-
Cash payments relating to other financing activities	3,785,075,271.21	3,692,653,879.65
Sub-total of cash outflows from financing activities	33,092,821,887.94	19,172,961,446.68
Net cash flow from financing activities	4,603,582,331.44	7,993,796,952.15
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(1,762,191.97)	2,222,988.55
V. Net increase in cash and cash equivalents	(929,003,889.44)	2,263,003,594.73
Add: Opening balance of cash and cash equivalent	14,321,098,931.85	9,308,355,856.20
VI. Closing balance of cash and cash equivalents	13,392,095,042.41	11,571,359,450.93